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The incidence of transitional cell carcinoma of the kidney and ureter is low and for that reason limited data exists regarding
the appropriate management of regional retroperitoneal lymph nodes. Lymph node metastases have consistently been associated
with an adverse prognosis. However, ﬁve-year cancer-speciﬁc survival following nephroureterectomy and lymphadenectomy for
patientswithlymph nodeinvolvement ranges from0–39%, suggestingatherapeuticbeneﬁt.Thisreview coverstheprimarytumor
characteristicsassociatedwithlymphnodeinvolvement,imagingofthelymphnodes,aswellastherationale,role,patientselection,
suggested anatomic templates, and technical considerations for lymphadenectomy.
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1.Introduction
Transitional cell carcinoma (TCC) of the kidney and ureter,
alternatively referred to as upper tract TCC (UT-TCC),
represents approximately 10% of malignancies arising from
the kidney and less than 5% of all urothelial malignancies,
which primarily occur in the bladder. In 2007, about 3000
cases of UT-TCC were diagnosed in the United States
compared to approximately 67000 cases of bladder cancer
[1, 2]. Within the upper urinary tract, TCC of the ureter
is less common than TCC of the renal pelvis by a ratio of
1:4 [3]. There are a variety of treatment options available
for UT-TCC including endoscopic excision or fulguration,
segmental resection, and radical surgery. The management
strategy selected primarily depends on the grade, stage,
location, presence of multifocality, renal functional reserve,
and the patient’s comorbid conditions. Largely due to
the infrequent disease incidence and variable lymph node
templates, the role of lymphadenectomy for UT-TCC is
not well deﬁned. Since TCC of the bladder can be cured
in approximately 25% of patients with regional nodal
spread following an extended lymph node dissection (LND)
and radical cystectomy, there is biologic plausibility to a
therapeutic role for lymphadenectomy in patients with UT-
TCC [4, 5]. This review will focus on the assessment and
surgical treatment of lymph nodes in UT-TCC.
2. Relationship of Stage and Nodal
Status with Outcome
Stage and grade of UT-TCC are independently associated
with recurrence and survival. The ﬁve-year actuarial survival
rates by primary tumor stage have been reported as 92%,
78%, 56%, and 0% for pathologic Ta-T1, T2, T3, and T4,
respectively. Patients with stage T4 disease have a dismal
median survival of 6 months [6, 7]. Tumor stage has
consistentlybeenshowntobethemostpowerfulpredictorof
disease-speciﬁc survival [8–10]. However, other factors like
higher grade, multifocality, lymphovascular invasion, and
previous cystectomy have also been associated with inferior
cancer-speciﬁc survival [10–12]. Transmural tumor growth
(pT3 or pT4) is less common in distal ureteral tumors
(33%) compared to midureteral (44%), proximal ureteral
(75%), or renal pelvis tumors (41%). There are several
plausible explanations for this observation. First, tumors in
the proximal ureter may be less likely to cause obstructive2 Advances in Urology
symptoms compared to distal ureteral tumors due to greater
distensibility of the proximal ureter and therefore present
at more advanced stages than tumors in the distal ureter.
Another proposed mechanism relates in part to the diﬀer-
ences in muscular layers between the proximal and distal
ureters. The distal ureter is encased by 3 layers of muscle
in comparison to the proximal ureter which only contains 2
relatively thin interlacing layers [13]. This diﬀerence could
explain the 2-fold higher incidence of transmural growth
of proximally located tumors as compared to more distally
located tumors [8].
Recent series show that up to 30% of patients with UT-
TCC have regional nodal involvement [7, 14]. All the tumor
characteristics that are associated with a poor prognosis
are associated with an increasing likelihood of lymph node
involvement. The likelihood of lymph node involvement
is associated with increasing stage and ranges from 4% in
noninvasive TCC of the upper tract to as high as 60% in
patients with pT4 disease [10]. Hall et al. reported on 139
patients with pTa, pT1, or pCIS followed for a median
of 64 months and not a single patient exhibited lymph
node involvement at surgery or on follow-up [6]. Similarly,
Kondo et al. reported on 42 patients with pTa, pT1, and
pCIS, and there were no instances of lymph node metastases
[14]. The ﬁve-year cancer-speciﬁc survival among patients
with lymph node involvement varies widely and ranges
from 0–39% [7, 14–17]( Table 1). Another study showed
lymph node involvement to be independently associated
with a three-fold increased risk of death at ﬁve years [7].
To our knowledge, no study deﬁnitively demonstrates a
survival beneﬁt for patients undergoing lymphadenectomy.
Interpretations of studies including an LND are challenging
for a number of reasons: (a) indications for an LND are
not standardized, (b) templates are highly variable, (c) often
only clinically suspicious lymph nodes are removed, and
(d) in many series LND is applied for staging purposes
and not therapeutic intent. Survival data from UT-TCC
series is also confounded by 50% of patients having a
history of bladder cancer and a signiﬁcant number having
cardiopulmonary morbidities, leading to competing risks of
mortality[7].However,Rabbanietal.comparedSurveillance
Epidemiology and End Results (SEER) outcomes for 657
patients who had UT-TCC diagnosed after bladder cancer
to 7839 patients who had de novo UT-TCC and found that
patients with de novo UT-TCC had a 1.7-fold increased
risk of cancer-related death [18]. Taken together, these data
suggest that stage, grade, lymphovascular invasion, and
tumor location are important factors that impact survival
and should be addressed when considering treatment of UT-
TCC and lymph node dissection.
3. Anatomic Distribution of
LymphNode Metastases
Anatomic lymph node mapping studies of the upper tract
are rare due to multiple factors, including relative rarity
of the disease, inconsistent dissection templates, and con-
ﬂicting data on the role of lymphadenectomy in UT-CC.
Table 1: Five-year cancer-speciﬁc survival for node-positive disease
following nephroureterectomy and lymph node dissection.
Number of
node-positive patients
Five-year
cancer-speciﬁc
survival
Johansson and
Wahlqvist [19] N/A 0%
Secin et al. [15]2 80%
Miyake et al. [17]1 3 0%
Novara et al. [7]2 712%
Kondo et al. [14]4 215%
Park et al. [20]1 1 27%
Roscigno et al. [16] 26 39%
Tumors of the renal pelvis and upper ureter drain into the
retroperitoneal lymph nodes, whereas tumors of the lower
ureter drain predominantly into the pelvic lymph nodes.
Work from Batata et al. in 1975 showed that node-positive
tumors of the renal pelvis can involve upper retroperitoneal
nodes (retrocrural, suprahilar, paracaval, paraaortic, and
interaortocaval) and extend caudally to the external iliac
lymph nodes [21]. Node-positive tumors of the middle
and lower third of the ureter can also involve both the
retroperitoneal and pelvic lymph nodes. Based on these ﬁnd-
ings, this group advocated an extensive LND encompassing
both regions. Involvement of more than one lymph node
has also been associated with an inferior 3-year cancer-
speciﬁc survival compared to only one node involved (58%
versus 16%) [22]. Kondo et al. recently reported the lymph
node drainage sites of 42 patients based on pathologic or
radiographic evidence of lymph node involvement. Tumors
of the lower ureter demonstrated an approximately 10%
rate of lymph node positivity, whereas tumors in the mid
to upper ureters demonstrated an increased likelihood of
positive lymph nodes (up to 42%). This was dependent on
tumor stage and very few tumors that were pathologic T1
or less had lymph node involvement. Tumors of the right
renal collecting system can metastasize to hilar, paracaval,
retrocaval, interaortocaval lymph nodes, and right common
iliac lymph nodes [23]. Rarely, in the setting of signiﬁcant
nodal disease, right-sided tumors will also metastasize to
preaortic or paraaortic nodes. [14]. Tumors of the left renal
collecting system may involve hilar, paraaortic, interaorto-
caval, and left common iliac lymph nodes [23]. Upper and
midureteral tumors may also involve the same side-speciﬁc
nodal regions as tumors of the renal pelvis, with midureteral
tumors harboring the potential to spread to lymph node
regions caudal to the inferior mesenteric artery extending
along the common iliac nodal chain [14]. The nodal basins
for tumors of the distal ureter include the external iliac,
obturator, and hypogastric regions. Although constrained
by limited lymph node dissections, these studies provide
updated information on the lymph node drainage of the
upper tracts in the current era.Advances in Urology 3
4. Imaging of Lymph Nodes
Since staging of TCC plays an important role in dictating
the course of therapy, accurate pretreatment imaging is
of utmost importance. Computed tomography (CT) and
magneticresonance (MR) imaging are the primary cross-
sectional imaging modalities by which the regional lymph
nodes are assessed. The rarity of UT-TCC has limited
studies addressing imaging of these lymph nodes. However,
imaging studies relating to TCC of the bladder can provide
valuable insight. CT imaging can correctly stage lymph
node involvement in over 70% of patients with muscle
invasive bladder cancer. However, almost 25% of patients
are understaged with clinically normal nodes on CT scan.
CT has shown 28% sensitivity, 93% speciﬁcity, 68% positive
predictive value, and 72% negative predictive value as relates
to lymph node involvement in bladder cancer [24]. Jager et
al. showed that MRI demonstrated a sensitivity, speciﬁcity,
and accuracy of 83, 98, 92%, respectively, when lymph
nodes were larger than 8–10mm in patients with TCC of
the bladder [25]. A common theme in most studies of CT
or MRI in the staging of TCC is the relative understaging
of lymph node involvement in radiographically “normal”
nodes. The role of Fluorodeoxyglucose- (FDG-) positron
emission tomography (PET) in the imaging of TCC of the
urinary tract has been limited because it is excreted into
the urine and hard to distinguish from tumor activity in
the bladder or nearby lymph nodes. FDG-PET has helped
to identify distant lymph node involvement and metastases
for patients with TCC of the bladder but not well studied
in UT-TCC [26]. However, with the advent and utilization
of other radiotracer agents not excreted in the urine, such
as 11C-choline, the future of PET imaging for UT-TCC
is promising. 11C-choline PET-CT has shown encouraging
preliminary data in detecting nodal spread of TCC of the
bladder with pathologic conﬁrmation of nodes as small as
5mm[27]. While it seems intuitive that imaging studies of
TCC of the bladder can be extrapolated to UT-TCC, this
is not proven. Given the limitations of preoperative nodal
imaging and the risk of understaging, LND remains the only
way to deﬁnitively assess lymph node involvement in UT-
TCC.
5. Role of Lymphadenectomy
Aspreviouslymentioned,sparsedataexisttoestablishawell-
deﬁned role or optimal extent of LND. Virtually every study
addressing LND for UT-TCC has been retrospective and
severely limited by nonuniform application of LND, variable
anatomicboundaries,andinconsistentselectionforadjuvant
therapy[6,9,14–16,20,28].Therefore,determiningwhether
LNDprovides a potential therapeutic beneﬁtorsimply oﬀers
more accurate surgical and pathologic staging is largely
unknown. Nevertheless, the pertinent observations detailed
above regarding lymph node metastases incidence, location,
and prognostic signiﬁcance have been made, subsequently
reproduced, and help inform contemporary patient counsel-
ing and surgical management.
6. Staging
Intuitively, retroperitoneal LND should improve the accu-
racy of pathologic staging and allow for more accurate
prognostic assessment. Therefore, complete surgical staging
consists of a radical nephroureterectomy (NU) and regional
LND. While no consensus has been established regarding the
appropriate and necessary extent of a regional LND, multiple
authors suggest patient-speciﬁc templates based on laterality
of the primary tumor, location of the primary tumor (renal
pelvis, upper/mid/lower ureter), and presence of radio-
graphic or intraoperative retroperitoneal lymphadenopathy
[14, 28, 29].
7. Therapeutic
While basic tenets of surgical oncology make it easy to
proclaim that LND improves pathologic staging, it is largely
unclear whether the time, eﬀort, or potential morbidity of
an LND is worthwhile from a therapeutic perspective. There
are currently three lines of evidence suggesting that LND
oﬀers the potential for increasing the probability of cancer-
speciﬁc survival. First, a proportion of patients with nodal
metastases, up to 39%, exhibit intermediate-term cancer-
free survival (Table 1) and highlight that regional nodal
involvement is compatible with the possibility of durable
cure. Second, multiple retrospective series, albeit with sub-
stantial limitations such as selection bias and the Will Rogers
phenomenon [30], have shown that LND is associated with
improved cancer-speciﬁc outcome [9, 16, 17, 28]. In a
Japanese study by Kondo et al. of 169 patients with localized
UT-TCC, a complete regional LND was associated with
a 50% decreased risk cancer-speciﬁc death [28]. Roscigno
et al. analyzed 132 patients undergoing NU for UT-TCC
and ﬁve-year cancer-speciﬁc survival was 67% versus 40%,
in favor of those having an LND [16]. Whether a patient
underwent an LND in these series was surgeon determined
and not prespeciﬁed. Therefore, factors such as patient age,
clinical characteristics of the cancer, preoperative imaging
features, comorbid diseases, and patient performance status
undoubtedly inﬂuenced the decision of whether an LND
was performed. We are unaware of any study that has
randomized patients based on preoperative characteristics to
inclusion or extent of LND. Until such a formal, prospective
analysis is performed we will continue to debate the merits,
value, and proper extent of an LND for UT-TCC. Third,
since TCC of the UT and bladder originate from the same
urothelial cells, it can be loosely extrapolated that patients
with regional nodal involvement may respond similarly to
surgicalexcision.SincetheincidenceofbladderTCCismuch
higherthanUT-TCC,aricherexperiencewithaccompanying
data has been established regarding the natural history
of surgically treated node-positive patients. Approximately
25% of patients with bladder TCC and pelvic lymph node
metastases will experience a durable recurrence-free survival
[31], and up to 35–40% of patients with limited node
involvement will experience low lymph node density or an
organ-conﬁned primary tumor [32, 33]. This attests to the
curative potential of surgery for a subset of patients with4 Advances in Urology
lymph-node metastases in TCC of the bladder and suggests a
similar possibility for those with node-positive UT-TCC.
8.PatientSelection
Without prospective studies utilizing standardized anatomic
templates, the selection of patients for LND at time of
treatment for UT-TCC remains uncertain. While other uro-
logic malignancies such as prostate, bladder, and testicular
cancer lack formal randomized data regarding the impact
of LND, much has been gleaned from the outcomes of
a uniformly applied, extensive LND consisting of similar
anatomic boundaries for each patient [32, 34, 35]. This has
not been done in a systematic manner for patients with UT-
TCC, therefore decisions regarding the application or extent
of LND must be drawn from weaker lines of evidence.
Among patients undergoing NU for UT-TCC, 16–23%
will experience a local recurrence, typically in the regional
lymphnodes[20,36].Forpatientswithureteraltumors,Park
et al. reported a 37% versus 7% local recurrence rate based
on the absence or presence of an LND, respectively [20].
Whether an LND may have prevented these recurrences,
decreased progression to systemic metastases, or improved
disease-freesurvivalisnotknown.However,withlocalrecur-
rence rates so high and their nearly universal association
with subsequent metastases and disease-speciﬁc mortality,
the beneﬁt of an LND appears to outweigh the risks.
The incidence of nodal metastases has been strongly
associatedwithprimarytumorstageandmultipleserieshave
reported that lymph node metastases in the setting of low
stage UT-TCC (≤pT1) are rare at surgery or on follow-up [6,
14].ThisdatainitiallysuggeststhatLNDmaybeexcludedfor
patients with low-stage disease however the gross limitations
of preoperative clinical staging preclude an accurate and
reliable prediction of ultimate pathologic stage. Therefore,
it is our belief that all patients undergoing treatment for
UT-TCC regardless of surgical approach (laparoscopic or
open) or type of surgery (segmental ureterectomy, partial
nephrectomy, or radical NU) should have a concomitantly
thorough regional LND.
9. Technical Considerations for
Lymph Node Dissection
As UT-TCC may originate from either the renal or ureteral
urothelium, the regional lymph nodes may vary and the
anatomic regions of LND should be planned accordingly.
Based on the regional anatomic drainage detailed above
and presuming that the surgeon prefers an extensive rather
than a suboptimal LND, recommendations regarding LND
anatomic boundaries can be oﬀered. The anatomic borders
of dissection for a left-sided renal pelvis, upper ureteral,
or midureteral tumor should, at the minimum, encompass
the paraaortic, preaortic, and interaortocaval nodes from
the level of the renal hilum to the aortic bifurcation. For a
right-sidedrenalpelvis,upperureteral,ormidureteraltumor
the removed node regions should include the paracaval,
precaval, and interaortocaval areas from the renal hilum to
the aortic bifurcation. For most midureteral tumors and
all distal ureteral tumors, regardless of side of origin, a
common iliac, external iliac, obturator, and hypogastric
lymphadenectomy should be performed.
The method of LND, either open or laparoscopic, is a
secondary concern compared to the primary intent, which
is a thorough and safe removal of regional lymph nodes.
Between 43–72% of patients undergoing open NU have a
simultaneous LND and it is our impression that patients
undergoing laparoscopic NU do so even less frequently [15,
16, 20, 28]. Busby et al. have recently compared patients
undergoing open and laparoscopic NU with LND and noted
a slightly higher lymph node yield for patients undergoing
the laparoscopic approach (median: 6 versus 3) [37]. The
authors do not state what proportion of patients requiring
NUhadanLND .Bothgroupsappeartoha veaninadequately
low yield and surgeon template preference can easily, and
likely did, account for the diﬀerences rather than surgical
approach.
The surgeon’s goals are to optimize pathologic staging,
minimize local recurrences, and potentially improve disease-
free survival. General technical concerns for retroperitoneal
LND include “split and roll” of the inferior vena cava and/or
aorta, meticulous hemostasis and lymphostasis, and readi-
ness to control and ligate lumbar vessels when necessary. For
left-sided templates, the left renal vein is positioned as the
superior border unless suprahilar adenopathy is present, in
such case the surgeon should consider a more cranial dis-
section. If bulky retroperitoneal metastases are bilateral and
resectable, ejaculatory function may be of concern. However,
since the median age at diagnosis of UT-TCC is typically
in the late 70s [38], this situation should be rare. Since the
sympathetic trunks, ganglia, and postsympathetic eﬀerents
are collectively responsible for antegrade ejaculation, their
preservation, either by nerve-sparing or a modiﬁed template
dissection [39], is essential to maintain normal ejaculatory
function.
10.Future
Given the aforementioned limitations in retroperitoneal
imaging, preoperative staging, and the devastating impact of
local recurrences, we feel that an LND using a standardized
template should be considered for all patients undergoing
NU. However, if more accurate imaging with novel modali-
ties such as lymphotrophic tracers, molecular agents, or PET
scans becomes available, the treatment paradigm for patients
with UT-TCC would be appropriately altered.
Neoadjuvant chemotherapy for patients with muscle-
invasive bladder TCC results in improved disease-speciﬁc
outcomes [40] and, given the parallels between bladder and
UT-TCC, may be ideally suited for patients with high-risk
UT-TCC. For UT-TCC, neoadjuvant chemotherapy has not
been adequately studied and may never, given its relative
rarity. Beside the potential for improving cancer control,
other beneﬁts may include optimizing renal function at the
time of administration, allowing for maximum doses of
the most active agents, and eliminating the possibility of
surgical complications delaying adjuvant therapy. Since theAdvances in Urology 5
gemcitabineandcisplatindoubletprovidessimilareﬃcacyto
traditional MVAC (methotrexate, vinblastine, doxorubicin,
and cisplatin) regimens in patients with bladder TCC, with
an improved safety proﬁle, neoadjuvant therapy for patients
with UT-TCC becomes even more attractive [41].
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